<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 24.6.2.5244
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
  <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
  <div>
    <div style="text-align: center; font-weight: bold;">As filed with the U.S. Securities and Exchange Commission on August 1, 2024</div>
    <div style="text-align: right; font-weight: bold;">Registration No. 333-</div>
    <div> <br>
    </div>
    <div>
      <div>
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; color: #000000; text-align: center;"></div>
    </div>
    <div style="font-weight: 400;"> <br>
    </div>
    <div style="text-align: center; margin-top: 4pt; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
    <div> <br>
    </div>
    <div>
      <div>
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; color: #000000; text-align: center;"></div>
    </div>
    <div style="text-align: center; margin-top: 12pt; font-size: 18pt; font-weight: bold;">FORM S-8</div>
    <div style="text-align: center; font-weight: bold;">REGISTRATION STATEMENT</div>
    <div style="text-align: center; font-weight: bold;">UNDER THE SECURITIES ACT OF 1933<font style="font-style: italic;">&#160;</font></div>
    <div> <br>
    </div>
    <div>
      <div>
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; color: #000000; text-align: center;"></div>
    </div>
    <div style="text-align: center; margin-top: 12pt; font-size: 24pt; font-weight: bold;">BRIDGEBIO PHARMA, INC.</div>
    <div style="text-align: center; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>
    <div> <br>
    </div>
    <div>
      <div>
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; color: #000000; text-align: center;"></div>
    </div>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="zcc2b0aaab6e44667a67c979100ef801d">

        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">Delaware</div>
          </td>
          <td colspan="1" style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">84-1850815</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">(State or other jurisdiction of incorporation or organization)</div>
          </td>
          <td colspan="1" style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">(I.R.S. Employer Identification No.)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: middle;"><br>
          </td>
          <td colspan="1" style="width: 2%; vertical-align: middle;"><br>
          </td>
          <td style="width: 49%; vertical-align: middle;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">3160 Porter Drive, Suite 250</div>
          </td>
          <td colspan="1" style="width: 2%; vertical-align: bottom;"><br>
          </td>
          <td style="width: 49%; vertical-align: bottom;"><br>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">Palo Alto, CA</div>
          </td>
          <td colspan="1" rowspan="1" style="width: 2%; vertical-align: bottom;"><br>
          </td>
          <td rowspan="1" style="width: 49%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">94304</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 49%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">(Address of Principal Executive Offices)</div>
          </td>
          <td colspan="1" rowspan="1" style="width: 2%; vertical-align: bottom;"><br>
          </td>
          <td rowspan="1" style="width: 49%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">(Zip Code)</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; margin-top: 12pt; font-weight: bold;">2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN</div>
    <div style="text-align: center; font-weight: bold;">(Full title of the plan)</div>
    <div style="text-align: center; margin-top: 12pt; font-weight: bold;">Brian C. Stephenson</div>
    <div style="text-align: center; font-weight: bold;">Chief Financial Officer</div>
    <div style="text-align: center; font-weight: bold;">BridgeBio Pharma, Inc.</div>
    <div style="text-align: center; font-weight: bold;">3160 Porter Drive, Suite 250</div>
    <div style="text-align: center; font-weight: bold;">Palo Alto, CA 94304</div>
    <div style="text-align: center; font-weight: bold;">(Name and address of agent for service)</div>
    <div style="font-weight: 400;"> <br>
    </div>
    <div style="font-weight: bold; text-align: center;">(650) 391-9740</div>
    <div style="text-align: center; font-weight: bold;">(Telephone number, including area code, of agent for service)</div>
    <div style="text-align: center; margin-top: 12pt; font-style: italic; font-weight: bold;">Copies to:</div>
    <div style="font-style: normal; font-weight: 400;"> <br>
    </div>
    <div style="font-weight: bold; text-align: center;">Mitchell S. Bloom, Esq.</div>
    <div style="text-align: center; font-weight: bold;">Maggie L. Wong, Esq.</div>
    <div style="text-align: center; font-weight: bold;">Natalie T. Martirossian, Esq.</div>
    <div style="text-align: center; font-weight: bold;">Goodwin Procter LLP</div>
    <div style="text-align: center; font-weight: bold;">3 Embarcadero Center, 28th Floor</div>
    <div style="text-align: center; font-weight: bold;">San Francisco, CA 94111</div>
    <div style="text-align: center; font-weight: bold;">Telephone: (415) 733-6000</div>
    <div style="font-weight: 400;"> <br>
    </div>
    <div style="font-weight: 400;">
      <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 100%; color: #000000; text-align: center;"></div>
    <div style="font-weight: 400;"> <br>
    </div>
    <div>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
      &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="zeb59ee6fa1a244aeb00b96cf911e8246">

        <tr>
          <td style="width: 40.1%; vertical-align: bottom;">
            <div>Large accelerated filer</div>
          </td>
          <td style="width: 4.92%; vertical-align: bottom;">&#9746;</td>
          <td style="width: 50.31%; vertical-align: bottom;">
            <div>Accelerated filer</div>
          </td>
          <td style="width: 4.67%; vertical-align: bottom;">&#9744;</td>
        </tr>
        <tr>
          <td style="width: 40.1%; vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 40.1%; vertical-align: bottom;">
            <div>Non-accelerated filer</div>
          </td>
          <td style="width: 4.92%; vertical-align: bottom;">&#9744;</td>
          <td style="width: 50.31%; vertical-align: bottom;">
            <div>Smaller reporting company</div>
          </td>
          <td style="width: 4.67%; vertical-align: bottom;">&#9744;</td>
        </tr>
        <tr>
          <td style="width: 40.1%; vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 40.1%; vertical-align: bottom;">&#160;</td>
          <td style="width: 4.92%; vertical-align: bottom;">&#160;</td>
          <td style="width: 50.31%; vertical-align: bottom;">
            <div>Emerging growth company</div>
          </td>
          <td style="width: 4.67%; vertical-align: bottom;">&#9744;</td>
        </tr>

    </table>
    <div style="margin-top: 12pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
      Section 7(a)(2)(B) of the Securities Act. &#9744;</div>
    <div>
      <div> <br>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">REGISTRATION OF ADDITIONAL SHARES</div>
    <div style="text-align: center; font-weight: bold;">PURSUANT TO GENERAL INSTRUCTION E</div>
    <div style="margin-top: 12pt;">Pursuant to General Instruction E of Form S-8, BridgeBio Pharma, Inc. (the &#8220;Registrant&#8221;) is filing this Registration Statement on Form S-8 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission (the
      &#8220;Commission&#8221;) to register 6,500,000 additional shares of its common stock reserved and available for issuance under the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (formerly known as the Amended and Restated
      BridgeBio Pharma, Inc. 2019 Stock Option and Incentive Plan) (the &#8220;2021 Plan&#8221;), which was approved by the Registrant&#8217;s stockholders at the Registrant&#8217;s 2024 Annual Meeting of Stockholders on June 21, 2024. In accordance with the instructional note to
      Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement. The contents of the Registrant&#8217;s Registration Statements on Form S-8 (File Nos.<font style="color: rgb(0, 0, 0);"> <a href="https://www.sec.gov/Archives/edgar/data/1743881/000119312519187461/d96131ds8.htm">333-232491</a>, <a href="https://www.sec.gov/Archives/edgar/data/1743881/000119312520060577/d895203ds8.htm">333-236872</a>, <a href="https://www.sec.gov/Archives/edgar/data/1743881/000119312520188049/d880620ds8.htm">333-239718</a>, <a href="https://www.sec.gov/Archives/edgar/data/1743881/000119312521016258/d708589ds8.htm">333-252394</a>, <a href="https://www.sec.gov/Archives/edgar/data/1743881/000119312522053534/d314869ds8.htm">333-263009</a> and <a href="https://www.sec.gov/Archives/edgar/data/1743881/000119312523136099/d21126ds8.htm">333-269600</a>),</font> filed with the
      Commission on July 1, 2019, March 4, 2020, July 7, 2020, January 25, 2021, February 25, 2022 and February 6, 2023, respectively, are hereby incorporated by reference pursuant to General Instruction E.</div>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">PART II</div>
    <div style="text-align: center; margin-top: 12pt; font-weight: bold;">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</div>
  </div>
  <div><br>
    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9a161a0d4402446287b703bfa7af0b1a" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

          <tr style="vertical-align: top;">
            <td nowrap="nowrap" style="text-align: right; vertical-align: top; width: 45pt;">
              <div style="text-align: left; font-weight: bold;">Item 8.</div>
            </td>
            <td style="text-align: left; vertical-align: top; width: auto;">
              <div style="font-weight: bold;"><u>Exhibits.</u></div>
            </td>
          </tr>

      </table>
    </div>
  </div>
  <div><br>
    <div style="margin-top: 6pt;">See the Exhibit Index below for a list of exhibits filed as part of this registration statement on Form S-8, which Exhibit Index is incorporated herein by reference.</div>
    <div> <br>
    </div>
    <div style="font-weight: bold; text-align: center;">EXHIBIT INDEX</div>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="z79accd0ac3a84e63a22691274b80925a">

        <tr>
          <td style="width: 6%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">Exhibit</div>
            <div style="text-align: center; font-weight: bold;">No.</div>
          </td>
          <td style="width: 94%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">Description</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle; width: 94%;">&#160;</td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1743881/000119312519189260/d763414dex31.htm">4.1</a></div>
          </td>
          <td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Form of Amended and Restated Certificate of Incorporation of the Registrant (1)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle; width: 94%;">&#160;</td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1743881/000119312520288071/d87012dex32.htm">4.2</a></div>
          </td>
          <td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Form of Amended and Restated Bylaws of the Registrant (2)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle; width: 94%;">&#160;</td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1743881/000119312519179321/d613995dex41.htm">4.3</a></div>
          </td>
          <td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Specimen Common Stock Certificate (3)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle; width: 94%;">&#160;</td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="ef20033300_ex5-1.htm">5.1*</a></div>
          </td>
          <td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Opinion of Goodwin Procter LLP</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle; width: 94%;">&#160;</td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="ef20033300_ex23-1.htm">23.1*</a></div>
          </td>
          <td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Consent of Independent Registered Public Accounting Firm to BridgeBio Pharma, Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle; width: 94%;">&#160;</td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="ef20033300_ex5-1.htm">23.2*</a></div>
          </td>
          <td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Consent of Goodwin Procter LLP (included in Exhibit 5.1)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle; width: 94%;">&#160;</td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#POWEROFATTORNEYANDSIGNATU">24.1*</a></div>
          </td>
          <td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Power of Attorney (included on signature page)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle; width: 94%;">&#160;</td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1743881/000095017024089326/bbio-ex10_2.htm">99.1</a></div>
          </td>
          <td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan and forms of award agreements thereunder (4)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: middle;">&#160;</td>
          <td style="vertical-align: middle; width: 94%;">&#160;</td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="exfilingfees.htm">107*</a></div>
          </td>
          <td style="width: 94%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Filing Fee Table</div>
          </td>
        </tr>

    </table>
    <div> <br>
      <div>
        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z614e865b5ad84ce1b1b36d12af86c6f0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

              <tr style="vertical-align: top;">
                <td style="text-align: right; vertical-align: top; width: 18pt;">
                  <div style="text-align: left;">*</div>
                </td>
                <td style="text-align: left; vertical-align: top; width: auto;">
                  <div>Filed herewith.</div>
                </td>
              </tr>

          </table>
        </div>
        <div><br>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="za819706b10074ca38214dff4f59679cf">

          <tr>
            <td style="width: 2.5%; vertical-align: top;">
              <div>(1)</div>
            </td>
            <td style="width: 97.5%; vertical-align: top;">
              <div>Filed as Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on July 3, 2019 and incorporated herein by reference.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 2.5%; vertical-align: top;">
              <div>(2)</div>
            </td>
            <td style="width: 97.5%; vertical-align: top;">
              <div>Filed as Exhibit 3.2 to the Registrant&#8217;s Registration Statement on Form S-4, filed on November 6, 2020 and incorporated herein by reference.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 2.5%; vertical-align: top;">
              <div>(3)</div>
            </td>
            <td style="width: 97.5%; vertical-align: top;">
              <div>Filed as Exhibit 4.1 to the Registrant&#8217;s Amendment No. 3 to Registration Statement on Form S-1, filed on June 24, 2019 and incorporated herein by reference.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 2.5%; vertical-align: top;">
              <div>(4)</div>
            </td>
            <td style="width: 97.5%; vertical-align: top;">
              <div>Filed as Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on August 1, 2024 and incorporated herein by reference.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
      <div style="margin-top: 12pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused
        this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Palo Alto, State of California, this 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> day of August, 2024.</div>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="zadbb7c5055a64c6f9087952565112e30">

          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div style="font-weight: bold;">BRIDGEBIO PHARMA, INC.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 12%; vertical-align: middle;">&#160;</td>
            <td style="width: 88%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 12%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 88%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Neil Kumar</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 12%; vertical-align: top;">&#160;</td>
            <td style="width: 88%; vertical-align: top;">
              <div>Neil Kumar, Ph.D.</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 12%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 88%; vertical-align: top;">
              <div>Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div style="font-weight: bold; text-align: center;"> <br>
      </div>
      <div style="font-weight: bold; text-align: center;"><a name="POWEROFATTORNEYANDSIGNATU"><!--Anchor--></a>POWER OF ATTORNEY AND SIGNATURES</div>
      <div style="margin-top: 12pt;">KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Neil Kumar and Brian C. Stephenson as such person&#8217;s true and lawful attorney-in-fact and agent with
        full power of substitution and resubstitution, for such person in such person&#8217;s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and
        to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and
        thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or
        substitutes of any of them, may lawfully do or cause to be done by virtue hereof.</div>
      <div style="margin-top: 12pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated below.</div>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="z0909aa175f2646b7944cdc71f174eacb">

          <tr>
            <td style="width: 31.79%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: bold;">Signature</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td style="width: 52.78%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: bold;">Title</div>
            </td>
            <td style="width: 14.42%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: bold;">Date</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td style="width: 52.78%; vertical-align: bottom;">&#160;</td>
            <td style="width: 14.42%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Neil Kumar</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.78%; vertical-align: top;">
              <div>Chief Executive Officer and Director</div>
            </td>
            <td rowspan="2" style="width: 14.42%; vertical-align: top;">
              <div style="text-align: center;">August 1, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top;">
              <div style="text-align: center;">Neil Kumar, Ph.D.</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.78%; vertical-align: top;">
              <div style="font-style: italic;">(Principal Executive Officer)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.78%; vertical-align: top;">&#160;</td>
            <td style="width: 14.42%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Brian C. Stephenson</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.78%; vertical-align: top;">
              <div>Chief Financial Officer</div>
            </td>
            <td rowspan="2" style="width: 14.42%; vertical-align: top;">
              <div style="text-align: center;">August 1, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top;">
              <div style="text-align: center;">Brian C. Stephenson, Ph.D., CFA</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.78%; vertical-align: top;">
              <div style="font-style: italic;">(Principal Financial Officer and Principal Accounting Officer)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.78%; vertical-align: top;">&#160;</td>
            <td style="width: 14.42%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Eric Aguiar</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.78%; vertical-align: top;">
              <div>Director</div>
            </td>
            <td rowspan="2" style="width: 14.42%; vertical-align: top;">
              <div style="text-align: center;">August 1, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top;">
              <div style="text-align: center;">Eric Aguiar, M.D.</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.78%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.78%; vertical-align: top;">&#160;</td>
            <td style="width: 14.42%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Jennifer E. Cook</div>
            </td>
            <td rowspan="2" style="width: 1%; vertical-align: top;">&#160;</td>
            <td rowspan="2" style="width: 52.78%; vertical-align: top;">
              <div>Director</div>
            </td>
            <td rowspan="2" style="width: 14.42%; vertical-align: top;">
              <div style="text-align: center;">August 1, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top;">
              <div style="text-align: center;">Jennifer E. Cook</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.78%; vertical-align: top;">&#160;</td>
            <td style="width: 14.42%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Douglas A. Dachille</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.78%; vertical-align: top;">
              <div>Director</div>
            </td>
            <td rowspan="2" style="width: 14.42%; vertical-align: top;">
              <div style="text-align: center;">August 1, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top;">
              <div style="text-align: center;">Douglas A. Dachille</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.78%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.78%; vertical-align: top;">&#160;</td>
            <td style="width: 14.42%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Ronald J. Daniels</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.78%; vertical-align: top;">
              <div>Director</div>
            </td>
            <td rowspan="2" style="width: 14.42%; vertical-align: top;">
              <div style="text-align: center;">August 1, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top;">
              <div style="text-align: center;">Ronald J. Daniels</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.78%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.78%; vertical-align: top;">&#160;</td>
            <td style="width: 14.42%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Andrea J. Ellis</div>
            </td>
            <td rowspan="2" style="width: 1%; vertical-align: top;">&#160;</td>
            <td rowspan="2" style="width: 52.78%; vertical-align: top;">
              <div>Director</div>
            </td>
            <td rowspan="2" style="width: 14.42%; vertical-align: top;">
              <div style="text-align: center;">August 1, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.79%; vertical-align: top;">
              <div style="text-align: center;">Andrea J. Ellis</div>
            </td>
          </tr>

      </table>
      <div>
        <div><br>
        </div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="zc9c465639ea04e5588760f91eb0343fe">

          <tr>
            <td style="width: 31.83%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Fred Hassan</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">
              <div>Director</div>
            </td>
            <td rowspan="2" style="width: 14.44%; vertical-align: top;">
              <div style="text-align: center;">August 1, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top;">
              <div style="text-align: center;">Fred Hassan</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">&#160;</td>
            <td style="width: 14.44%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Charles Homcy</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">
              <div>Director</div>
            </td>
            <td rowspan="2" style="width: 14.44%; vertical-align: top;">
              <div style="text-align: center;">August 1, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top;">
              <div style="text-align: center;">Charles Homcy, M.D.</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">&#160;</td>
            <td style="width: 14.44%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Andrew W. Lo</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">
              <div>Director</div>
            </td>
            <td rowspan="2" style="width: 14.44%; vertical-align: top;">
              <div style="text-align: center;">August 1, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top;">
              <div style="text-align: center;">Andrew W. Lo, Ph.D.</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">&#160;</td>
            <td style="width: 14.44%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Frank P. McCormick</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">
              <div>Director</div>
            </td>
            <td rowspan="2" style="width: 14.44%; vertical-align: top;">
              <div style="text-align: center;">August 1, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top;">
              <div style="text-align: center;">Frank P. McCormick, Ph.D.</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">&#160;</td>
            <td style="width: 14.44%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ James C. Momtazee</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">
              <div>Director</div>
            </td>
            <td rowspan="2" style="width: 14.44%; vertical-align: top;">
              <div style="text-align: center;">August 1, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top;">
              <div style="text-align: center;">James C. Momtazee</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">&#160;</td>
            <td style="width: 14.44%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Ali J. Satvat</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">
              <div>Director</div>
            </td>
            <td rowspan="2" style="width: 14.44%; vertical-align: top;">
              <div style="text-align: center;">August 1, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top;">
              <div style="text-align: center;">Ali J. Satvat</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">&#160;</td>
            <td style="width: 14.44%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Randal W. Scott</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">
              <div>Director</div>
            </td>
            <td rowspan="2" style="width: 14.44%; vertical-align: top;">
              <div style="text-align: center;">August 1, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top;">
              <div style="text-align: center;">Randal W. Scott, Ph.D.</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top;">&#160;</td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">&#160;</td>
            <td style="width: 14.44%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center;">/s/ Hannah A. Valantine</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">
              <div>Director</div>
            </td>
            <td rowspan="2" style="width: 14.44%; vertical-align: top;">
              <div style="text-align: center;">August 1, 2024</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.83%; vertical-align: top;">
              <div style="text-align: center;">Hannah A. Valantine, M.D.</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 52.72%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "ef20033300_s8.htm", "description": "S-8", "secsgml_size_bytes": 47021}]
{"company-data": {"conformed-name": "BridgeBio Pharma, Inc.", "cik": "0001743881", "assigned-sic": "2834", "organization-name": "03 Life Sciences", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-281190", "film-number": "241167739"}, "business-address": {"street1": "3160 PORTER DR.", "street2": "SUITE 250", "city": "PALO ALTO", "state": "CA", "zip": "94304", "phone": "(650) 391-9740"}, "mail-address": {"street1": "3160 PORTER DR.", "street2": "SUITE 250", "city": "PALO ALTO", "state": "CA", "zip": "94304"}, "former-company": {"former-conformed-name": "BridgeBio Pharma LLC", "date-changed": "20180618"}}
As filed with the U.S. Securities and Exchange Commission on August 1, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
BRIDGEBIO PHARMA, INC.
(Exact name of registrant as specified in its charter)
Delaware
84-1850815
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
3160 Porter Drive, Suite 250
Palo Alto, CA
94304
(Address of Principal Executive Offices)
(Zip Code)
2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN
(Full title of the plan)
Brian C. Stephenson
Chief Financial Officer
BridgeBio Pharma, Inc.
3160 Porter Drive, Suite 250
Palo Alto, CA 94304
(Name and address of agent for service)
(650) 391-9740
(Telephone number, including area code, of agent for service)
Copies to:
Mitchell S. Bloom, Esq.
Maggie L. Wong, Esq.
Natalie T. Martirossian, Esq.
Goodwin Procter LLP
3 Embarcadero Center, 28th Floor
San Francisco, CA 94111
Telephone: (415) 733-6000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of "large accelerated filer," "accelerated filer,"
      "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☒
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
      Section 7(a)(2)(B) of the Securities Act. ☐
REGISTRATION OF ADDITIONAL SHARES
PURSUANT TO GENERAL INSTRUCTION E
Pursuant to General Instruction E of Form S-8, BridgeBio Pharma, Inc. (the "Registrant") is filing this Registration Statement on Form S-8 (the "Registration Statement") with the Securities and Exchange Commission (the
      "Commission") to register 6,500,000 additional shares of its common stock reserved and available for issuance under the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (formerly known as the Amended and Restated
      BridgeBio Pharma, Inc. 2019 Stock Option and Incentive Plan) (the "2021 Plan"), which was approved by the Registrant's stockholders at the Registrant's 2024 Annual Meeting of Stockholders on June 21, 2024. In accordance with the instructional note to
      Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement. The contents of the Registrant's Registration Statements on Form S-8 (File Nos.
333-232491
,
333-236872
,
333-239718
,
333-252394
,
333-263009
and
333-269600
),
filed with the
      Commission on July 1, 2019, March 4, 2020, July 7, 2020, January 25, 2021, February 25, 2022 and February 6, 2023, respectively, are hereby incorporated by reference pursuant to General Instruction E.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8.
Exhibits.
See the Exhibit Index below for a list of exhibits filed as part of this registration statement on Form S-8, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
Exhibit
No.
Description
4.1
Form of Amended and Restated Certificate of Incorporation of the Registrant (1)
4.2
Form of Amended and Restated Bylaws of the Registrant (2)
4.3
Specimen Common Stock Certificate (3)
5.1*
Opinion of Goodwin Procter LLP
23.1*
Consent of Independent Registered Public Accounting Firm to BridgeBio Pharma, Inc.
23.2*
Consent of Goodwin Procter LLP (included in Exhibit 5.1)
24.1*
Power of Attorney (included on signature page)
99.1
2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan and forms of award agreements thereunder (4)
107*
Filing Fee Table
*
Filed herewith.
(1)
Filed as Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed on July 3, 2019 and incorporated herein by reference.
(2)
Filed as Exhibit 3.2 to the Registrant's Registration Statement on Form S-4, filed on November 6, 2020 and incorporated herein by reference.
(3)
Filed as Exhibit 4.1 to the Registrant's Amendment No. 3 to Registration Statement on Form S-1, filed on June 24, 2019 and incorporated herein by reference.
(4)
Filed as Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q, filed on August 1, 2024 and incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused
        this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Palo Alto, State of California, this 1
st
day of August, 2024.
BRIDGEBIO PHARMA, INC.
By:
/s/ Neil Kumar
Neil Kumar, Ph.D.
Chief Executive Officer
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Neil Kumar and Brian C. Stephenson as such person's true and lawful attorney-in-fact and agent with
        full power of substitution and resubstitution, for such person in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and
        to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and
        thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or
        substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated below.
Signature
Title
Date
/s/ Neil Kumar
Chief Executive Officer and Director
August 1, 2024
Neil Kumar, Ph.D.
(Principal Executive Officer)
/s/ Brian C. Stephenson
Chief Financial Officer
August 1, 2024
Brian C. Stephenson, Ph.D., CFA
(Principal Financial Officer and Principal Accounting Officer)
/s/ Eric Aguiar
Director
August 1, 2024
Eric Aguiar, M.D.
/s/ Jennifer E. Cook
Director
August 1, 2024
Jennifer E. Cook
/s/ Douglas A. Dachille
Director
August 1, 2024
Douglas A. Dachille
/s/ Ronald J. Daniels
Director
August 1, 2024
Ronald J. Daniels
/s/ Andrea J. Ellis
Director
August 1, 2024
Andrea J. Ellis
/s/ Fred Hassan
Director
August 1, 2024
Fred Hassan
/s/ Charles Homcy
Director
August 1, 2024
Charles Homcy, M.D.
/s/ Andrew W. Lo
Director
August 1, 2024
Andrew W. Lo, Ph.D.
/s/ Frank P. McCormick
Director
August 1, 2024
Frank P. McCormick, Ph.D.
/s/ James C. Momtazee
Director
August 1, 2024
James C. Momtazee
/s/ Ali J. Satvat
Director
August 1, 2024
Ali J. Satvat
/s/ Randal W. Scott
Director
August 1, 2024
Randal W. Scott, Ph.D.
/s/ Hannah A. Valantine
Director
August 1, 2024
Hannah A. Valantine, M.D.